$225.25 1.4%
BIIB Stock Price vs. AI Score (Last 150 days)
Data gathered: July 18

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Biogen

Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.

Price $225.25
Target Price Sign up
Volume 839,580
Market Cap $32.8B
Year Range $190.52 - $267.71
Dividend Yield 0%
PE Ratio 28.09
Revenue per Employee $1,107,519
Earnings Date August 1 '24
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '242.29B1.14B1.16B393M693M3.670
Q4 '232.39B1.57B820M250M623M3.300
Q3 '232.53B1.52B1.01B-68M372M4.360
Q2 '232.46B1.18B1.28B592M709M4.020
Q1 '232.46B1.28B1.19B388M577M3.400

Insider Transactions View All

Singhal Priya filed to sell 4,886 shares at $213.1.
April 3 '24
Singhal Priya filed to sell 4,886 shares at $221.2.
February 26 '24
Singhal Priya filed to sell 5,148 shares at $221.5.
February 21 '24
Rowinsky Eric K filed to buy 20,629 shares at $222.5.
February 20 '24
Singhal Priya filed to sell 4,097 shares at $245.9.
February 5 '24

Congress Trading View All

Politician Filing Date Type Size
Rohit Khanna
May 6, 24 Buy $1K - $15K
Rohit Khanna
May 6, 24 Buy $1K - $15K
Rohit Khanna
Apr 5, 24 Sell $1K - $15K

What is the Market Cap of Biogen?

The Market Cap of Biogen is $32.8B.

What is Biogen's PE Ratio?

As of today, Biogen's PE (Price to Earnings) ratio is 28.09.

How Many People Work at Biogen?

As of our latest update, Biogen employed approximately 8,725 people worldwide. However, it's important to note that Biogen's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Biogen's revenue per employee?

$1,107,519. To calculate Biogen's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

When does Biogen report earnings?

Biogen will report its next earnings on August 1 '24.

What is the current stock price of Biogen?

Currently, the price of one share of Biogen stock is $225.25.

How can I analyze the BIIB stock price chart for investment decisions?

The BIIB stock price chart above provides a comprehensive visual representation of Biogen's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biogen shares. Our platform offers an up-to-date BIIB stock price chart, along with technical data analysis and alternative data insights.

Does BIIB offer dividends to its shareholders?

As of our latest update, Biogen (BIIB) does not offer dividends to its shareholders. Investors interested in Biogen should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Biogen?

Some of the similar stocks of Biogen are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.